CTVA

The most significant stock event in the past six months was the completion of the spin-off of its seed and genetics business into Vylor Inc. (VYLR) on October 1, 2026, where shareholders received one VYLR share for each CTVA share, resulting in a nominal drop of over 80% in CTVA's stock price due to a structural value transfer. Following the spin-off, Corteva (CTVA) was moved to the S&P MidCap 400 index on October 6, 2026, replacing Olin Corp., which led to selling pressure from S&P 500 tracking funds. Despite this, analysts reacted positively, with JPMorgan upgrading Corteva to Overweight on October 6, 2026, with a $19 price target, and KeyBanc upgrading to Overweight on October 7, 2026, with a $17 price target, both citing undervaluation. In October 2026, Corteva, along with Chemours and DuPont, agreed to a $455 million settlement over PFAS-related claims, causing CTVA's stock to fall about 4.5%. Earlier, on July 30, 2026, Corteva reported its second-quarter 2026 earnings, beating EPS estimates but missing on revenue, and subsequently raised its full-year 2026 operating EPS guidance to $3.60-$3.80. In August 2026, the company also raised its full-year operating EBITDA forecast to between $4.1 billion and $4.3 billion.